Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$13.57 +1.3%	$13.94	$7.86 ▼ $17.75	$1.62B	1.77	2.19 million shs	637,066 shs
BHVN Biohaven	$13.88 +0.7%	$16.58	$13.75 ▼ $55.70	$1.42B	0.91	1.29 million shs	362,259 shs
DYN Dyne Therapeutics	$8.54 +4.4%	$11.63	$6.36 ▼ $47.45	$970.72M	1.08	1.83 million shs	1.91 million shs
PGEN Precigen	$1.66 +4.1%	$1.44	$0.65 ▼ $2.17	$488.52M	1.78	1.42 million shs	898,058 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-2.37%	-4.49%	-6.82%	+0.75%	+27.65%
BHVN Biohaven	-5.60%	-2.13%	-18.72%	-16.45%	-59.47%
DYN Dyne Therapeutics	-9.61%	-14.08%	-44.35%	+20.12%	-76.22%
PGEN Precigen	-2.15%	+11.97%	+6.00%	+35.90%	+11.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	1.4307 of 5 stars	3.4	1.0	0.0	0.0	1.7	0.6
BHVN Biohaven	3.1933 of 5 stars	4.5	1.0	0.0	1.8	2.5	0.6
DYN Dyne Therapeutics	3.4731 of 5 stars	4.5	3.0	0.0	2.4	2.5	0.0
PGEN Precigen	3.6936 of 5 stars	3.5	1.0	4.7	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	38.54% Upside
BHVN Biohaven	3.07	Buy	$58.46	321.19% Upside
DYN Dyne Therapeutics	3.00	Buy	$41.13	381.56% Upside
PGEN Precigen	3.00	Buy	$6.00	262.54% Upside

Current Analyst Ratings Breakdown

Latest PGEN, BHVN, ARQT, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00
6/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/11/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00
5/29/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$46.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	8.23	N/A	N/A	$1.35 per share	10.05
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
PGEN Precigen	$4.20M	116.29	N/A	N/A	$0.13 per share	12.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$1.04	N/A	N/A	N/A	-60.95%	-80.66%	-32.94%	8/13/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)

Latest PGEN, BHVN, ARQT, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.75	3.55	3.37
BHVN Biohaven	N/A	2.33	2.33
DYN Dyne Therapeutics	N/A	20.35	20.35
PGEN Precigen	N/A	3.53	3.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
BHVN Biohaven	88.78%
DYN Dyne Therapeutics	96.68%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
BHVN Biohaven	14.60%
DYN Dyne Therapeutics	14.14%
PGEN Precigen	47.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	108.00 million	Optionable
BHVN Biohaven	239	102.11 million	87.21 million	Optionable
DYN Dyne Therapeutics	100	113.67 million	90.06 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable

PGEN, BHVN, ARQT, and DYN Headlines

Recent News About These Companies

Precigen (NASDAQ:PGEN) Shares Up 6.6% - Time to Buy?

1 hour ago | marketbeat.com

Precigen: August Is Pivotal For This Biotech Innovator

July 7 at 7:03 PM | seekingalpha.com

Precigen, Inc. (PGEN) Latest Stock News & Headlines - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Precigen (NASDAQ:PGEN) Stock Price Passes Above Fifty Day Moving Average - Time to Sell?

July 3, 2025 | marketbeat.com

Precigen Announces Key Approvals at Annual Meeting

July 2, 2025 | theglobeandmail.com

Precigen (NASDAQ:PGEN) Stock Passes Above 50-Day Moving Average - Should You Sell?

June 24, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Earns Market Outperform Rating from JMP Securities

June 12, 2025 | marketbeat.com

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions

June 12, 2025 | finance.yahoo.com

Cantor Fitzgerald Estimates Precigen FY2026 Earnings

June 11, 2025 | marketbeat.com

J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)

May 20, 2025 | theglobeandmail.com

Precigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 17, 2025 | finanznachrichten.de

Cantor Fitzgerald maintains Overweight on Precigen stock

May 17, 2025 | uk.investing.com

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025 | prnewswire.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

April 16, 2025 | prnewswire.com

Is Precigen (PGEN) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Precigen options imply 20.1% move in share price post-earnings

March 20, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)

March 20, 2025 | markets.businessinsider.com

4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 Analysts

March 20, 2025 | benzinga.com

Precigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business Updates

March 20, 2025 | finanznachrichten.de

Precigen Reports Progress and Financial Results for 2024

March 19, 2025 | tipranks.com

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

March 19, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, BHVN, ARQT, and DYN Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$13.57 +0.18 (+1.34%)

As of 01:10 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Biohaven NYSE:BHVN

$13.88 +0.09 (+0.65%)

As of 01:11 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Dyne Therapeutics NASDAQ:DYN

$8.54 +0.36 (+4.40%)

As of 01:10 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Precigen NASDAQ:PGEN

$1.66 +0.07 (+4.09%)

As of 01:07 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time